[ February 27, 2019 ]
March 4, 2019– Quagen Pharmaceuticals. announced that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Imatinib Mesylate Tablets, generic for Gleevec® Tablets by Novartis. Quagen Pharmaceuticals’s Imatinib Mesylate Tablets product was developed in collaboration with Stason Pharmaceuticals Inc. and will be commercially manufactured by Stason in 100mg and 400mg product strengths. Quagen Pharmaceuticals plans to launch the product in the near future.